Indaptus Therapeutics (INDP) Investor presentation summary

Opportunity highlights

• Developing novel anti-cancer and anti-viral immunotherapies using gram-negative bacteria to activate immune pathways.

• Phase 1 trial of Decoy20 for solid tumors completed first two cohorts; multi-dose cohort initiated in May 2024.

• Over 30 patients dosed weekly, with some showing stable disease; safety data presented at ASCO and SITC in 2024.

• Focus shifting from weekly monotherapy to combination studies, with proof-of-concept data expected late 2025/early 2026.

• Potential applications span oncology, infectious diseases, and broader immunology.

Clinical development and observations

• Decoy20 clears from the body within 2 hours, supporting the pulse-prime hypothesis.

• Transient induction of over 50 cytokines/chemokines observed, with mostly mild to moderate, short-lived side effects.

• Multi-cohort safety data presented in 2024; additional efficacy and safety data expected in 2H 2025.

• Combination studies with checkpoint inhibitors and NSAIDs in mouse models showed up to 100% complete responses and immunological memory.

Technology and mechanism

• Decoy platform uses killed, modified E. coli to safely activate both innate and adaptive immune pathways.

• Decoy therapeutics provide brief, systemic immune activation, reducing long-term toxicity risks.

• Demonstrated broader immune activation compared to mono-specific TLR agonists and approved immunotherapies.